ProteaPex Therapeutics’ patented, platform technology of locally-delivered therapeutics
ProteaPex Therapeutics’ technology is a novel method of Matrix Metalloprotease inhibition
ProteaPex Therapeutics’ innovative disease modifying therapeutics
Chief Science Officer, Marina D'Angelo PhD., talks about Osteoarthritis Research
July 24, 2019
ProteaPex Pitches Periodontal Therapeutic
Dr. Marina D’Angelo, CSO, will pitch ECPF-2, the novel therapeutic to treat periodontal disease, to Fortune 500 companies and investors. The pitch was coordinated through the National Council of Entrepreneurial Tech Transfer (NCET2).
June 16, 2019
CSO Discusses ECPF-1, a Novel Osteoarthritis Therapeutic
Dr. Marina D’Angelo, CSO, discussed development of ECPF-1, the novel, injectable therapeutic that slows the progression of osteoarthritis.
April 9, 2019
ECPF-1 Poster Presented at Experimental Biology 2019
ProteaPex Therapeutics presented a poster concerning our proprietary human osteoarthritis culturing system (HOACs) used to test potential osteoarthritis therapeutics, like ECPF-1.
In January 2019, Dental Materials Journal accepted our manuscript detailing the in vitro dental model used to test ECPF-2 efficacy in increasing bond strength of tooth restorations
Extracellular Matrix Protection Factor (ECPF-1) is a novel, safe and effective intra-joint injection that reduces the pain and damage caused by osteoarthritis.
Extracellular Matrix Protection Factor-2 (ECPF-2), is a safe, non-antibiotic oral healthcare treatment that slows the damage associated with periodontal disease.
Extracellular Matrix Protection Factor-3 (ECPF-3) can block the cellular players that cause narrowing of airways in Chronic Pulmonary Obstructive Diesase (COPD) and asthma.
ProteaPex Therapeutics holds broad-based patents detailing a disruptive technology that can accommodate a platform of products to address many diseases.
Extracellular Matrix Protection Factor (ECPF) is a novel, safe and effective platform of locally delivered therapeutics. The ECPFs target diseases where abnormal breakdown of the organ tissue is a sign of pathology. The patented mechanism of action is unlike any other competitors currently in development.
ProteaPex Therapeutics, LLC holds a broad-based patent application detailing a disruptive technology that can accommodate a platform of products to address many diseases.
Chief Executive Officer
Jeff Boily is a serial entrepreneur and investor with over 30 years of global life sciences experience. Jeff's emerging company and fund raising experience includes start-ups, growth stage and turnaround in pharmaceuticals, biotechnology, drug delivery, medical devices, and clinical informatics.
Chief Science Officer
Marina D’Angelo, PhD has over 25 years of experience in cell differentiation and cartilage biology. The major emphasis of her research endeavors has been chondrocyte biology. Over the last 20 years she has studied the role of growth factors and enzymes in normal chondrocyte differentiation and the disease pathway, osteoarthritis.
Chief Medical Officer
Dr Selim has over 20 years of combined experience in bioinformatics, peptide design, cartilage and bone biology as well as pre-clinical and clinical research in medical device industry. He is co-inventor of the ECPF technology and has designed specific therapeutic peptides tailored to target pathological circuits.
Use this form to contact us about Partnering, Investment or for more Info...